Publications by authors named "Verena Engelstaedter"
Background: Mucin-1 is known to be over-expressed by various human carcinomas and is shed into the circulation where it can be detected in patient's serum by specific anti-Mucin-1 antibodies, such as the tumour marker assays CA 15-3 and CA 27.29. The prognostic value of Mucin-1 expression in ovarian carcinoma remains uncertain.
View Article and Find Full Text PDFPatients with advanced ovarian cancer (FIGO stage III) have a poor clinical prognosis. However, these patients show distinct differences in their survival time, possibly due to differing responses to chemotherapy and differing tumor biology. In contrast to histological subtype, grading and staging, which are known to affect a patient's prognosis, the impact of the human epidermal growth factor receptor 2 (Her-2/neu), topoisomerase IIα and epidermal growth factor receptor (EGFR) on survival remain inconclusive.
View Article and Find Full Text PDFHer-2/neu gene amplification is an established prognostic factor in breast cancer, and Her-2/neu protein is the target of the therapeutic monoclonal antibody Herceptin. More recently, topoisomerase IIα became a new focus of breast cancer research because of its role as a target for anthracycline therapy. Therefore, we compared Her-2/neu and topoisomerase IIα amplification/deletion in a large series of advanced breast cancer using fluorescence in situ hybridization.
View Article and Find Full Text PDFArticle Synopsis
- Previous studies indicated that BRCA-related epithelial ovarian cancer (EOC) may have better survival rates compared to sporadic EOC, but little research has focused on differences between BRCA genotypes.
- This study analyzed clinical characteristics and outcomes for BRCA1 and BRCA2 patients diagnosed with EOC from 1981 to 2008, identifying 197 cases with a median follow-up of 63 months.
- While no significant differences in event-free survival (EFS) were found, a non-significant trend suggested that BRCA2 patients had better overall survival (OS) at 5 years, particularly in advanced-stage disease, warranting further investigation.
Introduction: Although breast cancer is a major health problem worldwide, metastatic disease to the lower genital tract remains to be a rare event.
Case Report: A 64-year old woman was admitted to our hospital due to newly diagnosed ascites and peripheral edema. A computer tomography had shown peritoneal carcinosis but no clear evidence of an intraabdominal mass.